HIPEC: a narrative review of what HIPEC can do PART-2
Автор: Peritoneal Surface Oncology Group International
Загружено: 2025-11-26
Просмотров: 23
Описание:
The burden of improving survival in patients with peritoneal malignancies is borne by cytoreductive surgery. HIPEC in most situations has a secondary role to play. Yet HIPEC takes the centerstage when it comes to clinical trials, debates and discussion. How did this happen? Or how did we let this happen?"Lana Bijelic, chief, peritoenal malignany unit, CHU Moises Broggi and academic coordinator of European School of Peritoneal Surface Oncology (ESPSO) in conversation with #PaulSugarbaker, secretary general of the PSOGI.
➡ Will the Spanish Mitomycin C HIPEC trial be a positive trial?
➡ Is mitomycin C really the better drug for HIPEC in colorectal cancer? Does the choice of drug matter?
➡ In ovarian cancer, HIPEC has shown a benefit in patients who have received neoadjuvant chemotherapy. This is in contrast with the results in colorectal cancer where it is showing a benefit in patients undergoing surgery upfront. Why this difference ?
Listen on..
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
